Bank of New York Mellon’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$473M Sell
758,492
-6,919
-0.9% -$4.71M 0.08% 225
2026
Q1
$591M Buy
765,411
+1,169
+0.2% +$895K 0.11% 179
2025
Q4
$590M Buy
764,242
+92,612
+14% +$62.9M 0.1% 172
2025
Q3
$378M Buy
671,630
+15,006
+2% +$8.48M 0.07% 244
2025
Q2
$345M Sell
656,624
-41,629
-6% -$23.2M 0.07% 259
2025
Q1
$443M Buy
698,253
+8,990
+1% +$6.18M 0.09% 212
2024
Q4
$491M Sell
689,263
-25,813
-4% -$21.7M 0.09% 202
2024
Q3
$752M Sell
715,076
-149,166
-17% -$166M 0.14% 138
2024
Q2
$908M Sell
864,242
-22,302
-3% -$21.6M 0.17% 109
2024
Q1
$853M Sell
886,544
-62,031
-7% -$59M 0.16% 117
2023
Q4
$833M Sell
948,575
-18,839
-2% -$15.5M 0.17% 121
2023
Q3
$796M Buy
967,414
+2,666
+0.3% +$2.1M 0.18% 116
2023
Q2
$693M Sell
964,748
-29,220
-3% -$22.5M 0.15% 132
2023
Q1
$817M Buy
993,968
+9,496
+1% +$7.16M 0.18% 121
2022
Q4
$710M Sell
984,472
-38,252
-4% -$28.2M 0.16% 127
2022
Q3
$705M Buy
1,022,724
+64,867
+7% +$40.8M 0.17% 117
2022
Q2
$566M Buy
957,857
+40,799
+4% +$26.5M 0.13% 154
2022
Q1
$640M Buy
917,058
+33,036
+4% +$20.9M 0.12% 153
2021
Q4
$558M Buy
884,022
+3,207
+0.4% +$1.97M 0.1% 180
2021
Q3
$533M Buy
880,815
+22,199
+3% +$13.8M 0.1% 174
2021
Q2
$480M Buy
858,616
+12,578
+1% +$6.37M 0.09% 195
2021
Q1
$400M Buy
846,038
+17,774
+2% +$8.65M 0.08% 214
2020
Q4
$400M Buy
828,264
+8,138
+1% +$4.39M 0.09% 189
2020
Q3
$459M Buy
820,126
+46,975
+6% +$28.5M 0.11% 159
2020
Q2
$482M Buy
773,151
+160,589
+26% +$91.2M 0.13% 147
2020
Q1
$299M Buy
612,562
+11,889
+2% +$4.9M 0.1% 183
2019
Q4
$226M Sell
600,673
-101
-0% -$34K 0.06% 300
2019
Q3
$167M Sell
600,774
-2,032
-0.3% -$601K 0.05% 358
2019
Q2
$189M Sell
602,806
-2,576
-0.4% -$858K 0.05% 342
2019
Q1
$249M Buy
605,382
+13,539
+2% +$5.58M 0.07% 264
2018
Q4
$221M Sell
591,843
-13,101
-2% -$4.8M 0.07% 262
2018
Q3
$244M Buy
604,944
+7,520
+1% +$2.86M 0.06% 294
2018
Q2
$206M Buy
597,424
+1,055
+0.2% +$330K 0.06% 333
2018
Q1
$205M Sell
596,369
-22,041
-4% -$7.67M 0.06% 335
2017
Q4
$232M Sell
618,410
-26,608
-4% -$10.8M 0.06% 328
2017
Q3
$288M Sell
645,018
-124,768
-16% -$59.4M 0.08% 261
2017
Q2
$378M Sell
769,786
-112,081
-13% -$49M 0.11% 203
2017
Q1
$342M Buy
881,867
+237,157
+37% +$87.9M 0.09% 220
2016
Q4
$237M Buy
644,710
+1,249
+0.2% +$475K 0.07% 300
2016
Q3
$259M Sell
643,461
-8,507
-1% -$3.41M 0.08% 276
2016
Q2
$228M Sell
651,968
-19,679
-3% -$7.58M 0.07% 292
2016
Q1
$242M Sell
671,647
-141,489
-17% -$58.3M 0.07% 276
2015
Q4
$441M Sell
813,136
-91,702
-10% -$49.7M 0.13% 161
2015
Q3
$421M Sell
904,838
-30,002
-3% -$16.1M 0.13% 158
2015
Q2
$477M Sell
934,840
-496
-0.1% -$242K 0.13% 157
2015
Q1
$423M Sell
935,336
-9,774
-1% -$4.14M 0.11% 203
2014
Q4
$388M Buy
945,110
+2,405
+0.3% +$946K 0.1% 213
2014
Q3
$340M Sell
942,705
-44,945
-5% -$15.1M 0.09% 231
2014
Q2
$279M Sell
987,650
-25,618
-3% -$7.59M 0.08% 281
2014
Q1
$304M Sell
1,013,268
-189,651
-16% -$58.4M 0.08% 255
2013
Q4
$331M Sell
1,202,919
-38,489
-3% -$11.1M 0.09% 223
2013
Q3
$388M Buy
1,241,408
+162,887
+15% +$42.8M 0.12% 180
2013
Q2
$243M Buy
+1,078,521
New +$251M 0.08% 263

Other funds holding REGN

Bank of New York Mellon's REGN Position: Q2 2026 in Review

Bank of New York Mellon reduced its Regeneron Pharmaceuticals (REGN) stake by 0.9% in Q2 2026, selling an estimated $4.71M and leaving 758,492 shares worth $473M. The position accounts for 0.08% of the portfolio, ranked #225.

Bank of New York Mellon first reported a position in REGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $908M in Q2 2024. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Bank of New York Mellon held 758,492 shares of Regeneron Pharmaceuticals worth $473M as of Q2 2026.
  • Bank of New York Mellon sold 6,919 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $4.71M.
  • Regeneron Pharmaceuticals made up 0.08% of Bank of New York Mellon's portfolio in Q2 2026, its #225 holding.
  • Bank of New York Mellon first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Bank of New York Mellon's Regeneron Pharmaceuticals position peaked at $908M in Q2 2024.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.